The new WCG SiteReady is aimed at increasing the profitability of clinical research and also helps researchers to attract more opportunities for externally-funded clinical trials.
WCG executive chairman and CEO Donald Deieso said: “The research ecosystem is changing rapidly; protocols are increasingly complex, research teams are stretched thin, and patients are more informed than ever.
“Biopharmaceutical companies are seeking investigators who can perform clinical studies at the highest level of efficiency and integrity. Conversely, leading investigative sites desire opportunities to participate in the exciting advances being developed by the industry.”
WCG SiteReady combines processes and techniques with new technologies that are already deployed in the market and is a comprehensive, end-to-end solution that makes research easy to manage.
Reducing the administrative burden of regulatory compliance, WCG SiteReady streamlines contract and budget negotiation and increases patient enrollment in clinical trials.
WCG executive vice-president Jonathan Zung said: “Over the past two years, we helped the five largest institutions in our network to grow at annual rates exceeding 20%.
“Our clients achieved this growth by implementing efficiency measures while working to increase top-line revenue through new study acquisition.”
WCG’s institutional and investigator site network members have achieved 20% reduction in operational cycle-times, 15% decrease in study costs and 40% reduction in clinical trial negotiating timelines by using elements of the WCG SiteReady solution for several years.
In January this year, Market Intelligence & Insights, a division of WCG, has acquired First Clinical Research, which organises the Model Agreements & Guidelines International (MAGI) Clinical Research Conference.
